At the news
? BEARISHIMPACT 6/10 8-K filed Nov 3, 2026 at 16:47 ET
InMed Pharmaceuticals reported Q1 FY2027 results with a net loss of $2.33M, cash burn reducing cash to $1.09M (runway into mid-November), and shareholders' equity turning negative at -$1.20M. The company is pursuing a merger with Mentari Therapeutics (shareholder vote Nov 4) and has a Nasdaq compliance plan accepted through March 2027.
- Net loss of $2,330,778 for Q1 FY2027 vs $1,726,899 in Q1 FY2026
- Cash and cash equivalents fell to $1,094,488 from $2,194,413 at June 30, 2026
- Shareholders' equity turned negative at -$1,199,396 vs $1,075,007 at June 30, 2026
- Cash runway expected only into mid-November 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access